Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 363-367

  Bedikian, A Y ^a,c   Legha, S S ^a   Eton, O ^a   Buzaid, A C ^a   Papadopoulos, N ^a   Coates, S ^a   Simmons, T ^a   Neefe, J ^b   Von Roemeling, R ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b Sanofi Synthelabo Research   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Melanoma; Tirapazamine

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; MUSCLE CRAMP; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030913953     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008249232000     Document Type: Article

References (23)

1. Legha S. Current therapy for malignant melanoma. Semin Oncol 1989; 16: 34-44.
2. Costanzi J, Vaitkevicius V, Quagliana J et al. Combination chemotherapy for disseminated malignant melanoma. Cancer 1975: 35: 342-6.
3. Johnson D, Presant C, Einhorn L et al. Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: A phase II study of the Southeastern Cancer Study Group. Cancer Treat Rep 1985; 69: 821-4.
4. Legha S, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-9.
5. McClay E, Mastrangelo M, Berd D, Bellet R. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 1992; 50: 553-6.
6. Baker M, Zeman E, Hirst V, Brown J, Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxiciy. Cancer Res 1988; 48: 5947-52.
7. Cahill A, White I. Reductive metabolism of 3-amino-1,2,4,-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 1990; 11: 1407-11.
8. Dorie M, Brown J. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53: 4633-6.
9. Chary K, Higby D, Henderson E et al. A phase II study with high-dose cis-DDP. Wadley Med Bull 1976; 6: 37.
10. Goodnight JE, Moseley H, Eilber F et al. Cis-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 1979; 63: 2005-7.
11. Al-Sarraf M, Fletcher W, Oishi N et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma. Cancer Treat Rep 1982; 66: 31-5.
12. Voigt H, Meigel W, Meissner K et al. Experiences with high-dose cisplatin therapy in metastasized malignant melanoma. Onkologie 1982; 5: 120-9.
13. Mechl Z, Krejci P, Cis-diamminedichloroplatinum in the treatment of disseminated malignant melanoma. Neoplasma 1983; 30: 371-7.
14. Mortimer J, Chestnut J, Higano C, Goodman G. High dose cisplatin in metastatic melanoma: Comparison of two schedules. Proc Am Soc Clin Oncol 1988; 7: 254.
15. Mortimer J, Schulman S, MacDonald J et al. High-dose cisplatin in disseminated malanoma: A comparison of two schedules. Cancer Chemother Pharmacol 1990; 25: 373-6.
16. Glover D, Grabelsky S, Fox K et al. Clinical trials of WR-2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1989; 16: 201-4.
17. Buzaid A, Murren J, Durivage H. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 1991; 68: 1238-41.
18. Avril M, Ortoli J, Fortier-Beaulieu M et al. High-dose cisplatin (C) and WR 2721 in metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11: 344.
19. Verschraegen C, Kleeberg U, Mudler J et al. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma: A phase II study ol the EORTC malignant melanoma cooperative group. Cancer 1988; 62: 1061-5.
20. Casper E, Bajoriti D. Phase II trial of carboplatin in advanced malignant melanoma. Invest New Drugs 1990; 8: 187-90.
21. Chang A, Hunt M, Parkinson D et al. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group. Am J Clin Oncol 1993; 16: 152-5.
22. Holden S, Teicher A. Re-enhancement of alkylating agent activity by SR-4233 in the FsaII C murine fibrosarcoma. J Natl Cancer Inst 1992; 84: 187-93.
23. Bedikian AY, Legha S, Mavligit G et al. Treatment of uveal melanoma metastatic to the liver. A review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665-70.